TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02917213

Intervention type: OTHER
Intervention: Cardiac MRI
Description: A cardiac MR will be acquired a week and 6 months after enrollment. The protocol includes the following sequences: cine mode of short axes from LV base to apex, 2-3-4 chambers and STIR +T2 sequence. Perfusion during the administration of a bolus of 0.05 mmol / kg Gadovist®. 3D sequence of late enhancement of inversion-recovery. Images will be acquired after 10 min of the administration of a total of 0.2 mmol / g of Gadovist®. Intraventricular thrombosis will be monitored. Phase contrast sequences in three orthogonal planes will be acquired. Morphological parameters of LV function (LVEF), contractility (Wall Motion Score ), sphericity index, infarct size, area at risk, edema, microvascular obstruction and first-pass perfusion will be obtained.

Intervention type: OTHER
Intervention: Brain MRI
Description: A brain MR will be acquired a week and 6 months after enrollment. Axial, sagittal and coronal spin echo sequence in T1, axial images in diffusion sequences (DWI), enhanced spin echo T2 and FLAIR (fluid-attenuated inversion recovery) sequences shall be obtained. A cerebral infarction will be positive when finding the presence of a focal lesion of\> 3 mm in diameter that meets one of these three characteristics: (1) high signal on isotropic DWI images and low signal on the apparent coefficient map Broadcast (ADC). (2) Cavitary lesion hyperintense on T2, with no signal (or low) in the FLAIR sequence. (3) Hyperintense lesion T2 / T1 hypointense with prior distribution defect known or new in a follow-up study.
Study: NCT01951326

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 placebo capsules administered orally BID
Study: NCT04169542

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT02402049

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Natrum muriaticum 30C
Description: 3 globules of Natrum muriaticum applied once daily at days 7,8, and 9 after the start of the period.
Study: NCT01934036

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Obex
Description: After concluded the two months of treatment, patients will be follow-up during three months without consumption of Obex.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After concluded the two months of treatment, patients will be follow-up during three months without consumption of the placebo.
Study: NCT00875706

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Educational Intervention
Description: The intervention consists of two (2) different types of training, both to be delivered through a train-the-trainer approach. The first of these is coaching-supervision training for nurse managers and other supervisory personnel in the CLC units. The second component is a one-day training for DCWs on communication and managing problem behaviors associated with dementia. These two trainings build on validated training models that have been developed by PHINational, but will be adapted and customized to include VA-developed clinical content on the management of problem behaviors associated with dementia.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Educational Intervention
Description: The intervention consists of two (2) different types of training, both to be delivered through a train-the-trainer approach. The first of these is coaching-supervision training for nurse managers and other supervisory personnel in the CLC units. The second component is a one-day training for DCWs on communication and managing problem behaviors associated with dementia. These two trainings build on validated training models that have been developed by PHINational, but will be adapted and customized to include VA-developed clinical content on the management of problem behaviors associated with dementia.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Educational Intervention
Description: The intervention consists of two (2) different types of training, both to be delivered through a train-the-trainer approach. The first of these is coaching-supervision training for nurse managers and other supervisory personnel in the CLC units. The second component is a one-day training for DCWs on communication and managing problem behaviors associated with dementia. These two trainings build on validated training models that have been developed by PHINational, but will be adapted and customized to include VA-developed clinical content on the management of problem behaviors associated with dementia.
Study: NCT02917213

Intervention type: PROCEDURE
Intervention: Reveal LINQ insertable cardiac monitoring system
Description: A Reveal LINQ insertable cardiac monitoring system will be implanted following 1:1 patient unblinded randomization (device:no device). The device will be interrogated at a week after implantation and at 6 months, or if symptoms (palpitations or syncope) have activated the device memory.
Study: NCT04520256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Interactive Video Feedback
Description: Video-recorded messages are used to provide periodic feedback on progress with weight loss, dietary change, and physical activity. Additional videos provide dietary skills training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Interactive Video Feedback
Description: Video-recorded messages are used to provide periodic feedback on progress with weight loss, dietary change, and physical activity. Additional videos provide dietary skills training.
Study: NCT02402049

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lachesis 30C
Description: 3 globules of Lachesis applied once daily at days 7,8, and 9 after the start of the period.
Study: NCT00842712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered at a dose of 400 mg/m\^2 as intravenous infusion over 2 hours on Day 1 of Cycle 1 followed by 250 mg/m\^2 intravenous infusion over 1 hour once weekly on Days 8 and 15 of Cycle 1 and Days 1, 8, and 15 of all subsequent cycles until progressive disease, death, unacceptable toxicity, or consent withdrawal.
Study: NCT03789357

Intervention type: DIAGNOSTIC_TEST
Intervention: Aldosterone renin ratio
Description: Aldosterone Renin Ratio to screen for Primary Aldosteronism
Study: NCT05113134

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transvaginal natural orifice specimen extraction (NOSE)
Description: Under general anesthesia, patients who are planned to perform multiport laparoscopic surgery for resection of solid organs including kidney, liver, stomach, adrenal gland and bladder will undergo Transvaginal NOSE
Study: NCT05611385

Intervention type: OTHER
Intervention: Difference in development of Acute Lung Injury in Amphetamine positive and negative patients
Description: No Intervention

Intervention type: OTHER
Intervention: Difference in development of Acute Lung Injury in Amphetamine positive and negative patients
Description: No Intervention
Study: NCT00842712

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Cis 80 mg/m\^2 intravenous infusion on Day 1 + Vin 25 mg/m\^2 or Cis 75 mg/m\^2 intravenous infusion on Day 1 + Gem 1250 mg/m\^2 intravenous infusion on Days 1 and 8 of each 3-week cycle will be administered along with Cil and cetuximab as per Investigator's discretion up to a maximum of 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Cis 80 mg/m\^2 intravenous infusion on Day 1 + Vin 25 mg/m\^2 or Cis 75 mg/m\^2 intravenous infusion on Day 1 + Gem 1250 mg/m\^2 intravenous infusion on Days 1 and 8 of each 3-week cycle will be administered along with Cil and cetuximab as per Investigator's discretion up to a maximum of 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Cis 80 mg/m\^2 intravenous infusion on Day 1 + Vin 25 mg/m\^2 or Cis 75 mg/m\^2 intravenous infusion on Day 1 + Gem 1250 mg/m\^2 intravenous infusion on Days 1 and 8 of each 3-week cycle will be administered along with Cil and cetuximab as per Investigator's discretion up to a maximum of 6 cycles.
Study: NCT04704167

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fixation of double barrel vascularised fibula
Description: 3D titanium miniplate or 3D titanium mesh tray are used as a method of fixation for double barrel vascularized fibula
Study: NCT02402049

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sepia 30C
Description: 3 globules of Sepia applied once daily at days 7,8, and 9 after the start of the period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nux vomica 30C
Description: 3 globules of Nux vomica applied once daily at days 7,8, and 9 after the start of the period.
Study: NCT04704167

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fixation of double barrel vascularised fibula
Description: 3D titanium miniplate or 3D titanium mesh tray are used as a method of fixation for double barrel vascularized fibula
Study: NCT02402049

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pulsatilla 30C
Description: 3 globules of Pulsatilla applied once daily at days 7,8, and 9 after the start of the period.
Study: NCT02884674

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Repetitive Transcranial Magnetic Stimulation
Description: modulation of the electrical activity of the right inferior frontal gyrus cortex in order to reduce Obsessive Compulsive Disorders symptoms by Active Transcranial Magnetic Stimulation (TMS) targeting the right frontal inferior gyrus, 2 sessions per day, each session 5min30 day, during 10 consecutive days, using theta burst stimulation and using a TMS neuronavigated robot
Study: NCT02402049

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folliculinum 30C
Description: 3 globules of Folliculinum applied once daily at days 7,8, and 9 after the start of the period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Natrum muriaticum
Description: 3 globules of placebo Natrum muriaticum applied once daily at days 7,8, and 9 after the start of the period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Lachesis
Description: 3 globules of placebo Lachesis applied once daily at days 7,8, and 9 after the start of the period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Sepia
Description: 3 globules of placebo Sepia applied once daily at days 7,8, and 9 after the start of the period.
Study: NCT04520256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Interactive Video Feedback
Description: Video-recorded messages are used to provide periodic feedback on progress with weight loss, dietary change, and physical activity. Additional videos provide dietary skills training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Interactive Video Feedback
Description: Video-recorded messages are used to provide periodic feedback on progress with weight loss, dietary change, and physical activity. Additional videos provide dietary skills training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Interactive Video Feedback
Description: Video-recorded messages are used to provide periodic feedback on progress with weight loss, dietary change, and physical activity. Additional videos provide dietary skills training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Interactive Video Feedback
Description: Video-recorded messages are used to provide periodic feedback on progress with weight loss, dietary change, and physical activity. Additional videos provide dietary skills training.
Study: NCT02917213

Intervention type: OTHER
Intervention: Coagulation blood test
Description: 5 ml of peripheral blood will be obtained for assessment of prothrombotic markers at enrollment, at one week and 6 months after enrollment.

Intervention type: OTHER
Intervention: Transcranial Doppler monitoring
Description: A Transcranial Doppler monitoring will be performed in the first 24 hours after enrollment in order to detect High Intensity Transient Signals (HITs).
Study: NCT02884674

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Repetitive Transcranial Magnetic Stimulation
Description: Sham rTMS will be delivered using non active magnetic coil, targeting the right frontal inferior gyrus, 2 sessions per day, each session 5min30 day, during 10 consecutive days, using TMS neuronavigated robot. A subjective sensation will be obtained via frontal dermic electrical stimulation.
Study: NCT03551977

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCanCope with Pain
Description: The participants are free to use the Norwegian iCanCope with Pain app as much as they want during the 8 week intervention period. The only support available is technical support.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: iCanCope with Pain control
Description: The participants are free to use the Norwegian iCanCope with Pain control app as much as they want during the 8 week intervention period. The only support available is technical support.
Study: NCT00842439

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBI
Description: Participants will have have one hour sessions, once a week for 12 weeks, where they will meet with an interventionist to go over cognitive-behavioral skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBI
Description: Participants will have have one hour sessions, once a week for 12 weeks, where they will meet with an interventionist to go over cognitive-behavioral skills.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NUT
Description: Participants will be asked to take omega-3 supplements, calcium tablets, and multivitamins every day for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NUT
Description: Participants will be asked to take omega-3 supplements, calcium tablets, and multivitamins every day for 12 weeks.
Study: NCT02588703

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Coping Skills Treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Existing DUI program group counseling
Study: NCT04508751

Intervention type: OTHER
Group type: OTHER
Intervention: 3T Free-Breathing Fetal Magnetic Resonance Imaging
Description: Subject will have a one time MRI scan.

Intervention type: OTHER
Group type: OTHER
Intervention: 3T Free-Breathing Fetal Magnetic Resonance Imaging
Description: Subject will have a one time MRI scan.

Intervention type: OTHER
Group type: OTHER
Intervention: 3T Free-Breathing Fetal Magnetic Resonance Imaging
Description: Subject will have a one time MRI scan.
Study: NCT03770390

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical correction of pectus excavatum
Description: Surgical correction of pectus excavatum
Study: NCT04055142

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: electrocoagulation
Description: HIV homosexuals males with High-grade anal intraepithelial neoplasia will be randomized and electrocoagulation will be performed in 2-3 sessions (session every 2 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cidofovir 1% topical ointment
Description: HIV homosexuals males with High-grade anal intraepithelial neoplasia will be randomized and they will be treated with cidofovir 1% ointment (3 times per week during 8 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sinecatechins 10% topical ointment
Description: HIV homosexuals males with High-grade anal intraepithelial neoplasia will be randomized and they will be treated with sinecatechins 10% ointment (3 times per week during 8 weeks)
Study: NCT01975337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisporivir
Description: Alisporivir supplied as 200 mg oral capsules in blister packs (7 units per blister pack)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alisporivir
Description: Alisporivir supplied as 200 mg oral capsules in blister packs (7 units per blister pack)
Study: NCT03294135

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Encepur Adults
Description: One dose of the vaccine can be administered at any one unscheduled visit depending on the detection of NT below 10. It will be administered intramuscularly into the non-dominant deltoid.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Encepur Adults
Description: One dose of the vaccine can be administered at any one unscheduled visit depending on the detection of NT below 10. It will be administered intramuscularly into the non-dominant deltoid.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Encepur Adults
Description: One dose of the vaccine can be administered at any one unscheduled visit depending on the detection of NT below 10. It will be administered intramuscularly into the non-dominant deltoid.
Study: NCT03089879

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVGH Shigella sonnei 1790GAHB vaccine
Description: Single dose administered at Day 1, by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVGH Shigella sonnei 1790GAHB vaccine
Description: Single dose administered at Day 1, by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVGH Shigella sonnei 1790GAHB vaccine
Description: Single dose administered at Day 1, by intramuscular injection.
Study: NCT03213574

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Intraoperative fluids will be administer per the discretion of anesthesia provider and not per SVV data or study protocol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment Group
Description: FloTrac arterial line data will be used to administer fluid bolus, based on study algorithm.
Study: NCT02402049

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nux vomica
Description: 3 globules of placebo Nux vomica applied once daily at days 7,8, and 9 after the start of the period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pulsatilla
Description: 3 globules of placebo Pulsatilla applied once daily at days 7,8, and 9 after the start of the period.
Study: NCT03952000

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A 60 minute walk at 60% maximal oxygen uptake.
Study: NCT00613938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol (CG5503)
Description: 50mg capsule q4-6 hrs for 3 days
Study: NCT02402049

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Folliculinum
Description: 3 globules of placebo Folliculinum applied once daily at days 7,8, and 9 after the start of the period.
Study: NCT02346799

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workout Window Reminders
Description: Participants will receive emails at prespecified times reminding them to exercise, either during a specific two hour window or at any time during the day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workout Window Reminders
Description: Participants will receive emails at prespecified times reminding them to exercise, either during a specific two hour window or at any time during the day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workout Window Reminders
Description: Participants will receive emails at prespecified times reminding them to exercise, either during a specific two hour window or at any time during the day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workout Window Reminders
Description: Participants will receive emails at prespecified times reminding them to exercise, either during a specific two hour window or at any time during the day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Workout Incentive Payment
Description: Participants will be paid $3 or $7 for each workout completed during the appropriate times.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Workout Incentive Payment
Description: Participants will be paid $3 or $7 for each workout completed during the appropriate times.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Workout Incentive Payment
Description: Participants will be paid $3 or $7 for each workout completed during the appropriate times.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lump Incentive Payments
Description: Participants will receive $20 payments for completing post treatment survey.
Study: NCT01963598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1033 (SAR391786)
Study: NCT04075968

Intervention type: OTHER
Intervention: Cognitive exercise
Description: Cognitive exercise will be applied

Intervention type: OTHER
Intervention: Home exercise
Description: Home exercise will be applied
Study: NCT01564095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Marginal liver grafts are flushed with Tacrolimus (20ng/ml) solved in 1000 ml HTK preservation solution (duration: 15 min) ex vivo at the end of backtable preparation in the experimental group.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HTK/Placebo
Description: Marginal liver grafts are flushed with 1000 ml HTK preservation solution(duration: 15 min) ex vivo at the end of backtable preparation in the placebo group.
Study: NCT01963598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1033 (SAR391786)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1033 (SAR391786)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study: NCT02346799

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partner Assignment
Description: Participants will be required to have same workout window as partners.
Study: NCT01963598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study: NCT03652493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Tumoral evaluation every 3 cycles
Study: NCT01096615

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Description:~- capsule size 3~Composition of the product:~* 45 mg of microcristalline cellulose,~* 132 mg of maltodextrin,~* 3 mg of magnesium stearate.~Composition of the capsule:~* 46 mg of hypromellose,~* 1 mg of titanium dioxide.~Packaging:~Products are packaged in aluminium tubes of 30 capsules.~Storage:~The product should be stored in a fridge. Direction for use: subject should consume 1 capsule daily together with a meal, with a glass of water.~The study products will be consumed daily for 7 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus paracasei LP-33
Description: Description:~* minimum 2.0x109 CFU of Lactobacillus paracasei LP-33~* capsule size 3 1 capsule daily together with a meal, with a glass of water.
Study: NCT01987518

Intervention type: OTHER
Intervention: Procedure surgery behavioral and genetic diagnosis
Description: Observational Study

Intervention type: PROCEDURE
Intervention: quality of life after different type of surgery